August 11, 2022

Medical Trend

Medical News and Medical Resources

France will continue to use AstraZeneca and Johnson & Johnson vaccines

France will continue to use both AstraZeneca and Johnson & Johnson COVID-19 vaccines

 

France will continue to use both AstraZeneca and Johnson & Johnson COVID-19 vaccines.  The French Ministry of Health said it will continue to use AstraZeneca and Johnson & Johnson’s two COVID-19 vaccines.

France will continue to use AstraZeneca and Johnson & Johnson vaccines

 

On the 20th local time, the French Ministry of Health stated at the weekly vaccination briefing that the two COVID-19 vaccines produced by AstraZeneca and Johnson & Johnson were “essential” to achieve the French vaccination plan as scheduled.

The French Ministry of Health said that if the COVID-19 vaccine produced by AstraZeneca and Johnson & Johnson is used carefully, France will be able to complete the target of one dose of vaccination for 20 million people by mid-May and 30 million people by mid-June. Otherwise, the above goals will be difficult to achieve. The French Ministry of Health also emphasized that in a race against the COVID-19 epidemic, it cannot risk giving up a life-saving vaccine.

The COVID-19 vaccines produced by AstraZeneca and Johnson & Johnson have reported the side effects of thrombosis and even death after vaccination. On the 20th, European Medicines Management issued an announcement on the occurrence of blood clots after Johnson & Johnson vaccination, stating that Johnson & Johnson’s COVID-19 vaccine may indeed be related to rare cases of abnormal thrombosis with thrombocytopenia, but the benefits of vaccination still outweigh the disadvantages.

Currently, France only vaccinates AstraZeneca for people over 55 years of age. However, many people refused to receive the vaccine because they were worried about the side effects of blood clots. Johnson & Johnson also temporarily suspended supplies to Europe due to the side effects of thrombosis.

 

(source:internet, reference only)


Disclaimer of medicaltrend.org